Seha Biljana, Bogosavljevic Vojislav, Grujicic Danica, Djulejic Vuk, Milićević Mihailo, Ilic Rosanda, Cicarevic Koca, Jovanovic Marija, Kapor Slobodan
Department of Neurosurgery, University Clinical Centre of Serbia, Belgrade, SRB.
Department of Neurosurgery, University of Belgrade - Faculty of Medicine, Belgrade, SRB.
Cureus. 2025 Aug 6;17(8):e89485. doi: 10.7759/cureus.89485. eCollection 2025 Aug.
This study was conducted to evaluate the outcomes of repeat Gamma Knife surgery (GKS) in patients with recurrent trigeminal neuralgia (TN), identify predictors for retreatment, and characterize associated complications.
Among 198 patients initially treated with GKS for TN, 34 (17.2%) underwent a second procedure due to recurrent or persistent pain. After applying the eligibility criteria, 25 patients were analyzed. Factors associated with retreatment were assessed, and complications and pain relief outcomes following repeat GKS were evaluated.
Prior microvascular decompression (MVD) and lower initial radiation dose were significantly associated with need for retreatment (p < 0.001 and p = 0.014, respectively). Neurovascular conflict and prior rhizotomy were not statistically significant predictors. Facial hypoesthesia was the most common complication after repeat GKS (64%). Repeat treatment yielded moderate pain relief in most patients, but durable long-term benefit was limited, consistent with literature reporting 40-60% efficacy.
Repeat GKS is a valuable option for recurrent TN but presents a risk of sensory complications. Prior MVD and lower initial dose are important predictors of retreatment necessity, guiding individualized patient counseling and treatment planning.
本研究旨在评估复发性三叉神经痛(TN)患者再次接受伽玛刀手术(GKS)的疗效,确定再次治疗的预测因素,并描述相关并发症。
在198例最初接受GKS治疗TN的患者中,34例(17.2%)因复发或持续性疼痛接受了第二次手术。应用纳入标准后,对25例患者进行了分析。评估与再次治疗相关的因素,并评估再次GKS后的并发症和疼痛缓解情况。
既往微血管减压术(MVD)和较低的初始放射剂量与再次治疗的需求显著相关(分别为p < 0.001和p = 0.014)。神经血管冲突和既往神经根切断术不是有统计学意义的预测因素。面部感觉减退是再次GKS后最常见的并发症(64%)。再次治疗在大多数患者中产生了中度疼痛缓解,但持久的长期益处有限,这与文献报道的40%-60%的疗效一致。
再次GKS是复发性TN的一种有价值的选择,但存在感觉并发症的风险。既往MVD和较低的初始剂量是再次治疗必要性的重要预测因素,有助于指导个性化的患者咨询和治疗计划。